Clinical trial Recruiting at 1 site Observational Ages 18 and up

FAPI PET/CT to predict adverse cardiac events after PCI for chronic total occlusion

Official title: The Value of FAPI Imaging for the Prediction of Adverse Cardiovascular Events in Chronic Total Occlusion of Coronary Artery Disease (FACT-2 Trial)

Run by Beijing Chao Yang Hospital · NCT07020858 · Data updated 2026-11-12

This will test whether FAPI PET/CT scans done before PCI can help predict major heart problems within 12 months in adults with chronic total coronary occlusion.

More Chronic Coronary Syndrome trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment470 (estimated)
SponsorBeijing Chao Yang Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedApril 15, 2025
Main results expectedMarch 15, 2026
Study endsMarch 15, 2027
Registry record updatedJune 19, 2025
Trial IDNCT07020858 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with at least one untreated CTO (reference vessel ≥2.5 mm, TIMI 0 for ≥3 months) who are eligible for PCI, willing to undergo preprocedural FAPI PET/CT, and can provide informed consent.

Probably not a fit

Patients with contraindications to antiplatelet therapy, severe liver dysfunction, advanced renal failure (eGFR <30), limited life expectancy (<1 year), or pregnancy are excluded and unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center observational cohort of adults with at least one untreated chronic total occlusion who undergo baseline 18F-FAPI PET/CT prior to PCI and are followed for 12 months. The study will measure myocardial and plaque FAPI uptake and relate uptake levels to the incidence of major adverse cardiovascular events (MACE) after PCI. Where available, imaging features of plaque vulnerability (including OCT findings) and measures of adverse remodeling will be compared with FAPI signals. The goal is to determine whether noninvasive FAPI imaging provides prognostic information beyond standard clinical and angiographic data.

Why it matters

Potential benefit: If successful, FAPI PET/CT could identify CTO patients at higher risk of adverse events after PCI so clinicians can tailor follow-up and management.

How similar studies have gone: Preliminary data (the original FACT study) showed FAPI imaging may predict ventricular remodeling at 6 months, but long-term prognostic value and plaque-vulnerability correlations remain incompletely established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years.
2. Confirmed diagnosis of ≥1 untreated chronic total occlusion (CTO):Defined as complete occlusion of a major coronary artery or relevant collateral (reference vessel diameter ≥2.5 mm or confirmed by two independent interventional cardiologists), with TIMI flow grade 0 in the distal segment and duration ≥3 months.Preoperatively confirmed by coronary angiography or coronary computed tomography angiography (CTCA).
3. Willingness to undergo FAPI-PET imaging and receive PCI under imaging guidance.
4. Ability to provide written informed consent.

Exclusion Criteria:

1. Contraindications to antiplatelet therapy: Allergy or intolerance to aspirin, clopidogrel, or ticagrelor.
2. Severe liver dysfunction: Liver function parameters exceeding 3× the upper limit of normal.
3. Severe chronic kidney disease: Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m².
4. Life expectancy \<1 year due to non-cardiovascular comorbidities.
5. Pregnancy or women of childbearing potential (unless surgically sterile or using contraception).

Where it's running

  • Beijing Chaoyang Hospital,Capital Medical University,Beijing,China
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

  • Principal investigator: Lin Zhao, Dr — Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
  • Study coordinator: Shengwen Yang, Dr
  • Email: verayang1990@163.com
  • Phone: +8601085231480

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.